The V617F mutation of JAK2 is very uncommon in patients with thrombosis

Haematologica

Volumn 92, Issue 2, 2007, Pages 285-286

  Remacha, Angel F ^a   Estivill, Camino ^a   Sarda, M Pilar ^a   Mateo, José ^a   Souto, Joan Carles ^a   Canals, Carme ^a   Nomdedéu, Josep ^a   Fontcuberta, Jordi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Idiopathic thrombosis; JAK2 mutation

Indexed keywords

JANUS KINASE 2; HEMOGLOBIN;

AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; THROMBOSIS; WORLD HEALTH ORGANIZATION; BLOOD; COHORT ANALYSIS; FEMALE; GENETICS; LETTER; MALE; METABOLISM; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA;

AGED; COHORT STUDIES; FEMALE; HEMOGLOBINS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 33947529214     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10358     Document Type: Article

References (10)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification. Tumours of haematopoietic and lymphoid tissues. IARC press. Lyon 2001.
2. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005;105:22-30.
3. Goerttler PL, Marz E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, et al. MPD Research Consortium. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. The MPD Research Consortium. Haematologica 2005;90:851-3.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005;434:1144-8.
6. Breccia M, Morano SG, D'Andrea M, Russo E, D'Elia GM, Alimena G. Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management. Eur J Haematol 2005;75:396-400.
7. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997;23:411-8.
8. Acharya J, Westwood NB, Sawyer BM, Messinezy M, Burroughs AK, Mehta AB, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995;55:315-21.
9. Tirado I, Mateo J, Soria JM, Oliver A, Martinez-Sanchez E, Vallve C, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93:468-74.
10. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. General Haematology Task Force of the British Committee for Standards in Haematology. Br J Haematol 2005;130:174-95.